F-star Therapeutics, Inc. (FSTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 35 PARKWOOD DRIVE
CAMBRIDGE, CB22 3AT
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
MRQ
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 78,54918,52654,45547,63850,55524,730
Cash and cash equivalents 78,54918,52628,70914,72423,64910,684
Short-term investments   25,74632,91426,90614,046
Receivables  443    
Prepaid expense  982    
Other undisclosed current assets 6,1906,1143,5221,649580840
Total current assets: 84,73926,06557,97749,28751,13525,570
Noncurrent Assets
Operating lease, right-of-use asset 3,2812,7822,717
Property, plant and equipment 8877892,2342,319687522
Long-term investments and receivables    16,804 752
Long-term investments    16,804 752
Intangible assets, net (including goodwill) 33,66333,912    
Goodwill 14,89814,926    
Intangible assets, net (excluding goodwill) 18,76518,986    
Restricted cash and investments   234234484 
Other noncurrent assets 45161351673535
Total noncurrent assets: 38,28237,5445,22019,5241,2061,309
TOTAL ASSETS: 123,02163,60963,19768,81152,34126,879
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 9,32214,0585,0514,2474,4343,501
Interest and dividends payable  403   
Accounts payable 3,0814,5972,2101,8801,7001,519
Accrued liabilities 6,2419,4612,4382,3672,7341,982
Deferred revenue  300 
Debt   355   
Business combination, contingent consideration, liability 1,9072,080    
Other undisclosed current liabilities 906539    
Total current liabilities: 12,13516,9775,4064,2474,4343,501
Noncurrent Liabilities
Long-term debt and lease obligation: 2,7232,6222,869   
Liabilities, other than long-term debt 1,694440271933127
Other liabilities   271933127
Operating lease, liability 2,7232,6222,869
Business combination, contingent consideration, liability 1,694440    
Other undisclosed noncurrent liabilities 9,61257619,3698,51113,1286,333
Total noncurrent liabilities: 14,0293,63822,2658,70413,1596,360
Total liabilities: 26,16420,61527,67112,95117,5939,861
Equity
Equity, attributable to parent 96,85742,99435,52655,86034,74817,018
Common stock 212211
Additional paid in capital 176,80891,238161,924157,931113,98468,559
Accumulated other comprehensive loss (1,502)(1,077)(235)(5)(23)(7)
Accumulated deficit (78,451)(47,168)(126,165)(102,068)(79,214)(51,535)
Total equity: 96,85742,99435,52655,86034,74817,018
TOTAL LIABILITIES AND EQUITY: 123,02163,60963,19768,81152,34126,879

Income Statement (P&L) ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues 21,16711,256   352
Revenue, net 352
Gross profit: 21,16711,256   352
Operating expenses (51,881)(33,641)(33,021)(28,470)(21,253)(19,756)
Operating loss: (30,714)(22,385)(33,021)(28,470)(21,253)(19,404)
Nonoperating income (expense) (941)(849)1,25499936996
Investment income, nonoperating   1,25499936996
Other nonoperating expense (941)(849)    
Interest and debt expense (844) (542)   
Other undisclosed loss from continuing operations before equity method investments, income taxes  (2,386)    
Loss from continuing operations before equity method investments, income taxes: (32,499)(25,620)(32,309)(27,471)(20,884)(19,308)
Other undisclosed income from continuing operations before income taxes 844     
Loss from continuing operations before income taxes: (31,655)(25,620)(32,309)(27,471)(20,884)(19,308)
Income tax benefit 3721    
Loss from continuing operations: (31,283)(25,619)(32,309)(27,471)(20,884)(19,308)
Loss before gain (loss) on sale of properties:(31,283)(25,619)(32,309)(27,471)(20,884)(19,308)
Other undisclosed net income   8,2124,617  
Net loss: (31,283)(25,619)(24,097)(22,854)(20,884)(19,308)
Other undisclosed net income (loss) attributable to parent     (6,795)1,942
Net loss attributable to parent: (31,283)(25,619)(24,097)(22,854)(27,679)(17,366)
Other undisclosed net loss available to common stockholders, basic    (4,617)  
Net loss available to common stockholders, basic: (31,283)(25,619)(24,097)(27,471)(27,679)(17,366)
Interest on convertible debt  1,000    
Net loss available to common stockholders, diluted: (31,283)(24,619)(24,097)(27,471)(27,679)(17,366)

Comprehensive Income ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (31,283)(25,619)(24,097)(22,854)(20,884)(19,308)
Comprehensive loss: (31,283)(25,619)(24,097)(22,854)(20,884)(19,308)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (425)557(230)18(6,811)1,953
Comprehensive loss, net of tax, attributable to parent: (31,708)(25,062)(24,327)(22,836)(27,695)(17,355)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: